UK Life Science Strategy Urges Adoption Of Accelerated Access Review, As Govt Prepares Response
Executive Summary
A set of proposals in the recently published Life Sciences Industrial Strategy, aimed at improving the way new products are identified and made available under the NHS, reiterates ideas contained in the 2016 Accelerated Access Review. The government says it will respond to the review shortly.
You may also be interested in...
UK Industrial Strategy Offers ‘Substantial’ Life Science Investments Through New Sector Deal
The UK government has finally published its Industrial Strategy white paper, which includes a “sector deal” for the life sciences that promises “substantial” private and charitable sector investments.
UK To Offer Firms More Flexible Commercial Deals On ‘Transformative’ Drugs, Earlier Access To Market
Companies seeking to have their innovative drugs made available on the NHS in England could benefit from government plans to offer “transformative” new products access to the market up to four years earlier than under the standard assessment route.
New UK Pathway To Cut Access Times For Breakthrough Products By Up To Four Years
The government’s much heralded response to the UK’s Accelerated Access Review backs proposals such as an accelerated pathway for “transformative” new products, improved horizon scanning, and more flexible commercial arrangements. Former GSK CEO Sir Andrew Witty will chair a new group responsible for selecting products for the new pathway.